Skip directly to content

Partnership For Better Health

Developing strong partnerships with government, the NHS, patient organisations, other healthcare organisations and industry is fundamental to ensuring UK patients gain access to much needed medicines and vaccines.

 

Read our thought leadership articles below to learn more about what key challenges, we believe, need to be tackled to ensure medical breakthroughs of the future reach patients, and how the UK can continue to attract investment from the life sciences industry.


Erling Donnelly | 27th October 2020

Erling Donnelly PhD, UK Oncology Lead, discusses the effect breast cancer has across society, far beyond the individual receiving the diagnosis.


Darius Hughes | 15th October 2020

Darius Hughes, Head of UK Vaccines, discusses why the challenge of this year's winter flu season could be more critical than ever before.


Monica Nijher | 12th October 2020

Monica Nijher, UK Immunology & Inflammation Medical Lead, discusses why the threat of a second wave means the clinically vulnerable need our support more than ever.


Pfizer UK | 24th September 2020

Pfizer launches ‘VacciNation’, a vision for protecting the health, wealth and resilience of the UK by unlocking the personal and societal value of vaccines.


Pfizer UK | 25th August 2020

In the global battle against COVID-19, we're focusing on a technology called an mRNA vaccine. Learn more about the science behind mRNA vaccines.


Pfizer UK | 11th August 2020

Pfizer UK Oncology Medical Director,
Dr Olivia Ashman, discusses what the future holds for cancer care post COVID-19.


Erling Donnelly | 1st August 2020

Erling Donnelly PhD, UK Oncology Lead, reflects on the continued impact of smoking on the health of UK citizens and the need for us to support those quitting in response to COVID-19.


Dr Gillian Ellsbury | 31st July 2020

Dr Gillian Ellsbury, Medical Director for Vaccines, Pfizer UK & Ireland, discusses the importance of vaccinations to help keep our population healthy and well during the winter season.


Julian Thompson & Deborah Clark | 30th April 2020

Pfizer UK R&D leaders discuss the latest scientific developments and the essential role of partnerships and our colleagues during the COVID-19 crisis.


Erling Donnelly | 12th February 2020

Through breakthrough science and innovative new treatments, we are transforming survival rates. It is crucial that we now look at what it means to live with cancer and take steps to reduce the ‘ripple effect’.


Pfizer UK | 10th January 2020

Written by UK think tank Demos and supported by Pfizer, the report seeks to explore the multifaceted cost of cancer and the impact it has on patients, their families and friends, and UK society.


Dr Olivia Ashman | 12th June 2019

We need to set in place the right framework across the entire health system to ensure patients, particularly those affected by rare cancers, can benefit from the promise of genomic medicine.


Pfizer UK | 26th March 2019

We're proud to be leading the conversation on the AMR crisis, working closely with industry, government, NHS and other healthcare organisations to take a cross functional approach.


Owen Marks | 12th March 2019

There is a real opportunity here for us to embrace a renewed partnership and together deliver the treatment a generation of patients need.


Ben Osborn | 11th February 2019

We share the NHS’s ambition to deliver a radical upgrade in prevention and public health.


Pfizer UK | 31st July 2017

We commissioned PwC Strategy& to analyse the factors that make a country globally competitive in life sciences.

 

PP-PFE-GBR-3179 / Nov 2020